Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Keun-Wook Lee et al.|The Lancet Oncology|2020Cited by 190
1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort ADaniel V.T. Catenacci, Y-K. Kang, H. Park et al.|Annals of Oncology|2021Cited by 14